Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902664-25-002355
Filing Date
2025-05-15
Accepted
2025-05-15 09:31:29
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 8705
  Complete submission text file 0000902664-25-002355.txt   10546
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Subject) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-44055 | Film No.: 25949339
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 110 GREENE STREET SUITE 800 NEW YORK NY 10012
Business Address 110 GREENE STREET SUITE 800 NEW YORK NY 10012 212-937-4975
Avoro Capital Advisors LLC (Filed by) CIK: 0001633313 (see all company filings)

EIN.: 271007403 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A